Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9726223 | 0.84 | FFAR4 (0.36) | ALDH1A1ATRFFAR4 | |
| SCHEMBL29710998 | 0.84 | ALOX5 (0.41) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL10687705 | 0.83 | FFAR4 (0.36) | ALDH1A1ATRFFAR4 | |
| SCHEMBL1256244 | 0.83 | ALOX15 (0.40) | ALDH1A1ATRFFAR4 | |
| Hydrochloric Acid SCHEMBL9235440 | 0.83 | ALOX5 (0.41) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL1902302 | 0.83 | IDO1 (0.40) | KDM4EALDH1A1ATRFFAR4 | |
| SCHEMBL29263829 | 0.82 | ADORA2A (0.40) | ALDH1A1MAPTATRFFAR4 | |
| SCHEMBL637798 | 0.80 | PTPN1 (0.44) | ATRFFAR4 | |
| SCHEMBL8952075 | 0.80 | PLA2G2D (0.37) | ATRFFAR4 | |
| SCHEMBL15690778 | 0.79 | FFAR4 (0.38) | PARP1TRPA1ATRFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | claimed |
| WO-2000027394-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2000-05-18 | — | — | WO | claimed |
| EP-0198797-A2 | Parasiticide | CIBA-GEIGY AG (CH) | 1986-10-22 | — | — | EP | claimed |
| CN-116730995-B | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-116730995-A | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-114634512-A | Compound as Bruton's tyrosine kinase inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1794145-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032851-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| EP-0198797-B1 | PARASITICIDE | CIBA-GEIGY AG (CH) | 1990-01-31 | — | — | EP | disclosed |
| US-4859783-A | INTERMEDIATE FOR PESTICIDES | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4722935-A | 2,2-DIFLUORO-4-(2*,4*-DINITRO-6*-TRIFLUOROMETHYLANILINO)-1, 3-BENZODIOXOLE | CIBA-GEIGY CORPORATION (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0198797-A2 | Parasiticide | CIBA-GEIGY AG (CH) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | ALOX15, ALOX15B, ALOX12 | PARP1 2047/4885TRPA1 1809/4885CYP11B1 30/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | PARP1 4138/4885TRPA1 4408/4885CYP11B1 4028/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | PARP1 4579/4885TRPA1 4407/4885CYP11B1 4515/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | PARP1 4583/4885TRPA1 4408/4885CYP11B1 4525/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | PARP1 4650/4885TRPA1 4192/4885CYP11B1 4317/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | PARP1 4594/4885TRPA1 4388/4885CYP11B1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.